Margaret T. Kasner, MD

Panelists discuss how treating secondary AML in the community setting requires a multifaceted approach, emphasizing early diagnosis, risk stratification, timely referral when necessary, and close collaboration with academic centers to provide optimal patient care.

Panelists discuss how the decision to refer a patient with secondary AML from community practice to an academic or specialized leukemia program should be based on a combination of disease complexity, treatment requirements, and the community center's capabilities, while emphasizing the importance of ongoing collaboration and education to enhance patient care across all settings.

Panelists discuss how community settings face unique challenges in delivering intensive chemotherapy regimens for secondary AML, including limited resources and expertise, but can implement best practices and leverage potential benefits of community-based care to provide effective treatment.

Panelists discuss how the NCCN guidelines recommend intensive chemotherapy options, including traditional 7+3 and CPX-351, for newly diagnosed high-risk or secondary AML patients, with treatment selection based on individual patient factors and potential adverse effects.

Panelists discuss how identifying candidates for allogeneic transplant in secondary acute myeloid leukemia involves a comprehensive assessment of disease characteristics, patient factors, and timing considerations, while also evaluating fitness for intensive chemotherapy induction using specific criteria to guide treatment decisions.

Panelists discuss how involving patients and caregivers in the treatment decision-making process for secondary acute myeloid leukemia (AML) requires clear communication, education about options, and consideration of individual values and preferences to ensure informed and shared decision-making.

Panelists discuss how comprehensive molecular and cytogenetic testing at diagnosis is crucial for accurate risk stratification, treatment selection, and prognostication in secondary acute myeloid leukemia (AML), while acknowledging the challenges of obtaining timely results, especially in community settings.

Panelists discuss how secondary acute myeloid leukemia (AML) generally carries a poorer prognosis compared to de novo AML, necessitating careful consideration of treatment goals and open communication with patients about their outlook.

Panelists discuss how secondary acute myeloid leukemia (AML) presents unique challenges in diagnosis, classification, and treatment due to its complex pathogenesis and evolving classification criteria.

Discussion centered around optimal strategies to effectively treat, and improve outcomes for, patients with FLT3-ITD AML.

Recommendations for community oncologists concerning the treatment of fit patients diagnosed with AML.

Eunice S. Wang, MD opens a discussion with other panelists concerning the benefits of germline testing in AML, NCCN guidelines for molecular testing, and how molecular testing in AML is advancing over time.

Experienced clinicians highlight the role of biomarker testing in AML for optimal patient care and treatment selection.

Moderator Naval G. Daver, MD introduces expert panelists and leads an overview of Acute Myeloid Leukemia, focusing on the importance of timely diagnosis and risk assessment for patients with AML.

Closing out their discussion on the management of acute myeloid leukemia, expert panelists share their excitement for the future evolution of the treatment landscape.

A comprehensive review of emerging treatment options and how they may fit into the treatment landscape of acute myeloid leukemia.

Shared insight on how treatments can be optimally sequenced in patients with relapsed/refractory acute myeloid leukemia.

Expert perspectives on the potential role of IDH1-targeted therapy, olutasidenib, in patients with relapsed/refractory acute myeloid leukemia.

Centering its discussion on relapsed/refractory acute myeloid leukemia, the panel highlights broader treatment strategies in this setting.

Before closing out their discussion on first-line treatment options for patients with AML, expert oncologists reflect on the role of stem cell transplant in AML.

A comprehensive review of novel venetoclax-based combination therapy in patients unfit for intensive chemotherapy who are diagnosed with AML.

In the setting of IDH-mutated AML, panelists consider optimal treatment options in patients unfit for intensive chemotherapy.

A brief overview of mainstay treatment options in the first-line setting of AML for patients deemed unfit for intensive chemotherapy.

Expert oncologists highlight challenges in the setting of TP53-mutated AML and consider appropriate treatment strategies.

Comprehensive discussion on the emergence of CPX-351 as a first-line treatment option for patients with acute myeloid leukemia.

Shared insight on IDH-mutated acute myeloid leukemia and appropriate first-line treatment options in this setting.

Expert perspectives on the emergence of FLT3-targeted therapies and their role in the first-line setting of acute myeloid leukemia management.

Centering focus on first-line treatment modalities, panelists highlight the ongoing role of intensive chemotherapy in the management of AML.

Expert oncologists reflect on risk stratification in acute myeloid leukemia and the process of categorizing patients into ‘fit’ versus ‘unfit’ subsets.

In light of novel targeted agents made available to patients with AML, panelists consider the value of timely molecular testing in this setting.